Sector Category: Life Sciences

June 6, 2020

Ventyx Biosciences

Developing selective inhibitors of TYK2 for autoimmune diseases.

November 1, 2018

Focused on the commercialization of spectacles with digital lens technology.

June 13, 2018

Focused on the development of first-in-class therapeutics for NASH and other metabolic, inflammatory and fibrotic diseases.

October 17, 2017

Acquired by Agilent Technologies. Developer of tools for measuring cell metabolism.

October 17, 2017

Acquired by Welsh, Carson, Anderson & Stowe. Developer of solutions for the treatment of complex spinal pathologies.

October 17, 2017

Acquired by C.R. Bard. Developer of endovascular devices for the treatment of coronary and peripheral CTO.

October 17, 2017

Acquired by Amgen. Focused on the development of a small molecule therapy for dyslipidemia.

October 17, 2017

Acquired by Johnson & Johnson. Focused on the development of drug-eluting stents to treat coronary artery disease.

October 17, 2017

Acquired by Cephalon. Focused on the development of a biologic therapy for the treatment of asthma.

October 17, 2017

Acquired by Amgen. Focused on the development of an oncolytic vaccine for melanoma and head and neck cancer.

October 17, 2017

Acquired by Allergan. Focused on the development of a small molecule therapy for the treatment of NASH.

October 17, 2017

Focused on the development of a drug-based solution to reduce the failure rate of AV Fistulas in dialysis patients.